BiotechTube
Curavac

Curavac

Leuven, Belgium· Est.
curavac.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

CuraVac is a private, clinical-stage biotech focused on creating potentially curative immunotherapies for autoimmune diseases. Its core platform utilizes complementary peptides to retrain the immune system, aiming for long-term remission. The company is advancing its lead candidate, CV-MG02, towards a Phase 2 trial for Myasthenia Gravis, with a pipeline targeting other major autoimmune conditions like Multiple Sclerosis and Type 1 Diabetes. CuraVac operates with a lean, network-based team and holds Orphan Drug Designation for its lead program in both the US and EU.

Autoimmune Diseases

Technology Platform

Targeted Active Therapy platform using complementary peptides to induce long-term immunity against specific autoantigens.

Funding History

2
Total raised:$5M
Grant$1.8M
Seed$3.2M

Opportunities

Positive Phase 2 data for CV-MG02 would validate the novel complementary peptide platform, attracting partnership deals and funding for expansion into larger autoimmune indications like Multiple Sclerosis and Type 1 Diabetes.
Orphan Drug Designation in the US and EU provides regulatory and commercial advantages for the lead program.

Risk Factors

The primary risk is clinical failure of CV-MG02 in Phase 2, which would undermine the core technology.
As a pre-revenue private company, securing sufficient funding to complete clinical trials is a persistent financial risk.
The platform faces competition from established and novel immunotherapies in a crowded autoimmune market.

Competitive Landscape

CuraVac operates in the highly competitive autoimmune disease space, competing against large pharma companies and biotechs developing monoclonal antibodies, JAK inhibitors, and other immunomodulators. Its key differentiator is the aim for a targeted, potentially curative therapy using its novel complementary peptide approach, rather than chronic immunosuppression.

More companies in Immunotherapy / Immuno-Oncology →More companies in Belgium →